Cargando…

Gene Expression in the Hippocampus in a Rat Model of Premenstrual Dysphoric Disorder After Treatment With Baixiangdan Capsules

Objective: To explore the targets, signal regulatory networks and mechanisms involved in Baixiangdan (BXD) capsule regulation of premenstrual dysphoric disorder (PMDD) at the gene transcription level, since the etiology and pathogenesis of PMDD are not well understood. Methods: The PMDD rat model wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Sheng, Sun, Peng, Guo, Yinghui, Chen, Jingxuan, Wang, Jieqiong, Song, Chunhong, Li, Zifa, Xue, Ling, Qiao, Mingqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242977/
https://www.ncbi.nlm.nih.gov/pubmed/30483168
http://dx.doi.org/10.3389/fpsyg.2018.02065
_version_ 1783371880769519616
author Wei, Sheng
Sun, Peng
Guo, Yinghui
Chen, Jingxuan
Wang, Jieqiong
Song, Chunhong
Li, Zifa
Xue, Ling
Qiao, Mingqi
author_facet Wei, Sheng
Sun, Peng
Guo, Yinghui
Chen, Jingxuan
Wang, Jieqiong
Song, Chunhong
Li, Zifa
Xue, Ling
Qiao, Mingqi
author_sort Wei, Sheng
collection PubMed
description Objective: To explore the targets, signal regulatory networks and mechanisms involved in Baixiangdan (BXD) capsule regulation of premenstrual dysphoric disorder (PMDD) at the gene transcription level, since the etiology and pathogenesis of PMDD are not well understood. Methods: The PMDD rat model was prepared using the resident-intruder paradigm. The rats were tested for aggressive behavior, and those with scores in the lowest 30% were used as controls, while rats with scores in the highest 30% were divided into a PMDD model group, BXD administration group and fluoxetine administration group, which were evaluated with open-field tests and aggressive behavior tests. We also analyzed gene expression profiles in the hippocampus for each group, and verified differential expression of genes by real-time PCR. Results: Before and after BXD or fluoxetine administration, scores in the open-field test exhibited no significant differences. The aggressive behavior of the PMDD model rats was improved to a degree after administration of both substances. Gene chip data indicated that 715 genes were differentially expressed in the control and BXD groups. Other group-to-group comparisons exhibited smaller numbers of differentially expressed genes. The effective targets of both drugs included the Htr2c, Cdh3, Serpinb1a, Ace, Trpv4, Cacna1a, Mapk13, Mapk8, Cyp2c13, and Htr1a genes. The results of real-time PCR tests were in accordance with the gene chip data. Based on the target genes and signaling pathway network analysis, we have elaborated the impact and likely mechanism of BXD in treating PMDD and premenstrual irritability. Conclusion: Our work contributes to the understanding of PMDD pathogenesis and the mechanisms of BXD treatment. We speculate that the differentially expressed genes could participate in neuroactive ligand-receptor interactions, mitogen-activated protein kinase, calcium, and gamma-aminobutyric acid signal transduction.
format Online
Article
Text
id pubmed-6242977
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62429772018-11-27 Gene Expression in the Hippocampus in a Rat Model of Premenstrual Dysphoric Disorder After Treatment With Baixiangdan Capsules Wei, Sheng Sun, Peng Guo, Yinghui Chen, Jingxuan Wang, Jieqiong Song, Chunhong Li, Zifa Xue, Ling Qiao, Mingqi Front Psychol Psychology Objective: To explore the targets, signal regulatory networks and mechanisms involved in Baixiangdan (BXD) capsule regulation of premenstrual dysphoric disorder (PMDD) at the gene transcription level, since the etiology and pathogenesis of PMDD are not well understood. Methods: The PMDD rat model was prepared using the resident-intruder paradigm. The rats were tested for aggressive behavior, and those with scores in the lowest 30% were used as controls, while rats with scores in the highest 30% were divided into a PMDD model group, BXD administration group and fluoxetine administration group, which were evaluated with open-field tests and aggressive behavior tests. We also analyzed gene expression profiles in the hippocampus for each group, and verified differential expression of genes by real-time PCR. Results: Before and after BXD or fluoxetine administration, scores in the open-field test exhibited no significant differences. The aggressive behavior of the PMDD model rats was improved to a degree after administration of both substances. Gene chip data indicated that 715 genes were differentially expressed in the control and BXD groups. Other group-to-group comparisons exhibited smaller numbers of differentially expressed genes. The effective targets of both drugs included the Htr2c, Cdh3, Serpinb1a, Ace, Trpv4, Cacna1a, Mapk13, Mapk8, Cyp2c13, and Htr1a genes. The results of real-time PCR tests were in accordance with the gene chip data. Based on the target genes and signaling pathway network analysis, we have elaborated the impact and likely mechanism of BXD in treating PMDD and premenstrual irritability. Conclusion: Our work contributes to the understanding of PMDD pathogenesis and the mechanisms of BXD treatment. We speculate that the differentially expressed genes could participate in neuroactive ligand-receptor interactions, mitogen-activated protein kinase, calcium, and gamma-aminobutyric acid signal transduction. Frontiers Media S.A. 2018-11-13 /pmc/articles/PMC6242977/ /pubmed/30483168 http://dx.doi.org/10.3389/fpsyg.2018.02065 Text en Copyright © 2018 Wei, Sun, Guo, Chen, Wang, Song, Li, Xue and Qiao. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychology
Wei, Sheng
Sun, Peng
Guo, Yinghui
Chen, Jingxuan
Wang, Jieqiong
Song, Chunhong
Li, Zifa
Xue, Ling
Qiao, Mingqi
Gene Expression in the Hippocampus in a Rat Model of Premenstrual Dysphoric Disorder After Treatment With Baixiangdan Capsules
title Gene Expression in the Hippocampus in a Rat Model of Premenstrual Dysphoric Disorder After Treatment With Baixiangdan Capsules
title_full Gene Expression in the Hippocampus in a Rat Model of Premenstrual Dysphoric Disorder After Treatment With Baixiangdan Capsules
title_fullStr Gene Expression in the Hippocampus in a Rat Model of Premenstrual Dysphoric Disorder After Treatment With Baixiangdan Capsules
title_full_unstemmed Gene Expression in the Hippocampus in a Rat Model of Premenstrual Dysphoric Disorder After Treatment With Baixiangdan Capsules
title_short Gene Expression in the Hippocampus in a Rat Model of Premenstrual Dysphoric Disorder After Treatment With Baixiangdan Capsules
title_sort gene expression in the hippocampus in a rat model of premenstrual dysphoric disorder after treatment with baixiangdan capsules
topic Psychology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242977/
https://www.ncbi.nlm.nih.gov/pubmed/30483168
http://dx.doi.org/10.3389/fpsyg.2018.02065
work_keys_str_mv AT weisheng geneexpressioninthehippocampusinaratmodelofpremenstrualdysphoricdisorderaftertreatmentwithbaixiangdancapsules
AT sunpeng geneexpressioninthehippocampusinaratmodelofpremenstrualdysphoricdisorderaftertreatmentwithbaixiangdancapsules
AT guoyinghui geneexpressioninthehippocampusinaratmodelofpremenstrualdysphoricdisorderaftertreatmentwithbaixiangdancapsules
AT chenjingxuan geneexpressioninthehippocampusinaratmodelofpremenstrualdysphoricdisorderaftertreatmentwithbaixiangdancapsules
AT wangjieqiong geneexpressioninthehippocampusinaratmodelofpremenstrualdysphoricdisorderaftertreatmentwithbaixiangdancapsules
AT songchunhong geneexpressioninthehippocampusinaratmodelofpremenstrualdysphoricdisorderaftertreatmentwithbaixiangdancapsules
AT lizifa geneexpressioninthehippocampusinaratmodelofpremenstrualdysphoricdisorderaftertreatmentwithbaixiangdancapsules
AT xueling geneexpressioninthehippocampusinaratmodelofpremenstrualdysphoricdisorderaftertreatmentwithbaixiangdancapsules
AT qiaomingqi geneexpressioninthehippocampusinaratmodelofpremenstrualdysphoricdisorderaftertreatmentwithbaixiangdancapsules